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coside-associated-nephrotoxicity (ANN) for MDD were
determined by a retrospective chart review of 262 ran-
domly sampled patients who received gentamicin for the
treatment of serious gram-negative bacterial infections
between January 1, 1990 and March 30, 1998. The inci-
dence of ANN was 3.1%. Event rates for ODD protocol
for both clinical effectiveness and ANN were determined
to be 82.2% and 5.8%, respectively based on an exten-
sive review of the current literature. Time-in-motion
studies were performed to determine personnel costs for
all nursing and pharmacy activities. Decision analysis
was used to determine the CE of the two protocols. RE-
SULTS: The results were unexpected based on reports in
the literature predicting substantial cost savings with the
use of ODD programs. In the base case analysis the ex-
pected per patient cost value for MDD with CPS and
ODD protocols was $241 and $237 respectively. However,
MDD with CPS was determined to be more cost-effective
than ODD due to slightly increased rate of clinical effec-
tiveness and a decrease in the rate of ANN (average CE
ratios  $281 versus $287, respectively). Both one-way
and two-way sensitivity analyses were performed by
varying the two key parameters of clinical effectiveness
and ANN. The model was robust to alterations in these
key parameters. CONCLUSION: This CE analysis ques-
tions the benefit of implementing an ODD program when
compared to a more traditional MDD protocol managed
by a CPS for aminoglycoside dosing.
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OBJECTIVES: To determine if the 51 items in the
Schizophrenia Outcomes Assessment Project (SOAP-51)
instrument should be scored using weighted or un-
weighted items. METHODS: 193 community-based indi-
viduals with schizophrenia (average age 46.3yr, 46.6%
female) rated the importance of each item in the SOAP-
51 twice, 4 weeks apart, using a 10cm verbally anchored
(“not important to me” to “very important to me”), hor-
izontal line with a numerical scale progressing in units of
10 from 0 (not)–100 (most). RESULTS: Results are
based on 180 valid and complete surveys in the first ad-
ministration; there were also 171 in the second. The
items ranged from a low of 56.7  35.5 (How important
is it for you to have sexual relationships in your life?) to a
high of 89.1  18.4 (How important is it for you that
your medication helps you?): 1 item scored in the 50s, 2
in the 60s, 16 in the 70s, and 33 in the 80s. Six of 8 aver-
age item factor scores (self-concept, work/role, mental
health, medication effects, activities of daily living, and
physical functioning) had weights in the 80s ranging
from 80.4  18.7 to 85.1  13.3; however, two were in
the 70s: 79.1  15.5 (satisfaction) and 75.4 (interper-
sonal. There was no difference between the importance
weights of the 8 factors nor the 51 items (p  0.05).
CONCLUSIONS: It is appropriate to use an unweighted
summary for calculating the factor scores in the SOAP-
51. It is apparent that in the SOAP item reduction pro-
cess, items considered to be of import to the clients were
retained in the final instrument.
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OBJECTIVES: Little information is available comparing
the treatment course and charges of newly diagnosed pa-
tients with depression treated with either sertraline
(SER), venlafaxine (VEN) or venlafaxine sustained-release
(VXR) in the managed care setting. This analysis aimed
to determine the impact on treatment course and depres-
sion-related charges of selecting SER, VEN or VXR as
first line pharmacotherapy for newly diagnosed patients.
METHODS: Retrospective intent-to-treat analysis of an
integrated database of medical and pharmacy charges
(PharMetric’s Integrated Outcomes database 07/98–06/99)
including patients aged 18–65 who were diagnosed with
depression [ICD-9: 296.2, 296.3, 300.4, 311] and who
initiated SER, VEN or VXR therapy within the same 30-
day period. Patients with documented previous mental
disorders/treatment were excluded. Depression-related
treatment charges for the 6-month period following treat-
ment initiation were compared using log-linear regres-
sion. Cohorts were comparable with respect to prescrib-
ing physician (psychiatry vs. other). RESULTS: 19,129
patients were included in the analysis (SER  15,222;
VEN  1032; VXR  2875). VXR patients were more
likely to augment therapy compared to VEN or SER
(18% vs. 13% and 12%; p  0.05). VEN patients were
more likely to switch to other medications than VXR or
SER (33% vs. 21% and 16%; p  0.05). After control-
ling for differences in age, gender, managed care plan,
pre-treatment history of resource utilization, physician
specialty type, index RX year, and switching/augmenta-
tion, VEN and VXR patients incurred 13% and 30%
higher depression-related charges, respectively, than pa-
tients initiated on SER (p  0.05 for both comparisons).
CONCLUSIONS: Treatment of depression with sertra-
line was associated with significantly less augmentation/
switching, and lower depression-related charges than ven-
